Skip to content

TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk

TRIGR - Trial to Reduce IDDM in the Genetically at Risk

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00179777
Acronym
TRIGR
Enrollment
5156
Registered
2005-09-16
Start date
2002-05-06
Completion date
2017-09-30
Last updated
2021-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1

Keywords

Diabetes Mellitus, Type 1, Genetic Predisposition to Disease, Infant Nutrition, Primary Prevention

Brief summary

The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) is an international effort to conduct a primary prevention nutrition trial for type 1 (insulin-dependent) diabetes. The TRIGR study was targeted at newborns who are at genetic risk for type 1 diabetes because their mother, father and/or full sibling has type 1 diabetes. All families were encouraged to breast feed their infants for as long as possible. Prior to birth, the child was randomly assigned to receive one of two infant formulas, should formula be required prior to 8 months of age. The study determined whether weaning to a possibly protective infant formula decreases these children's chances of developing diabetes - as it does in the animal models for diabetes.

Detailed description

The hypothesis for this study is that weaning to an extensively hydrolyzed infant formula will decrease the incidence of type 1 diabetes in subjects with risk-associated HLA genotypes and a first degree relative with type 1 diabetes, as it does in all relevant animal models for the disease. Specific Aims: I.a: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of diabetes-predictive auto-antibodies in subjects with risk-associated HLA genotype and a first degree relative with type 1 diabetes (mother, father and/or full sibling). I-b: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of clinical diabetes in subjects with risk-associated HLA genotype and an affected first degree relative. A secondary aim is to determine relationships between cow's milk antibodies, a measure of cow's milk exposure, and diabetes-associated auto-antibodies. The mother of the unborn child is recruited during pregnancy. Randomization to one of two infant formulas takes place before birth (after 35 weeks gestation) or immediately after birth. Experimental Arm: Use of extensively hydrolysed cow's milk based infant formula when needed in supplementation or substitution for breast milk through 6-8 months from birth. Control Arm: Use of non-hydrolysed cow's milk based infant formula when needed in supplementation or substitution for breast milk through 6-8 months from birth. All families were encouraged to breast feed their infants for as long as possible. The study infant formula was only used if exclusive breast feeding ceases before 8 months of age. Cord blood for genotyping was obtained at birth, or failing that from a heel prick by 7 days of age. Only subjects with genotypes indicating increased genetic risk for type 1 diabetes remained in the intervention trial. All other subjects were withdrawn from the study. All subjects were followed until the youngest subject turns age 10 years.

Interventions

DIETARY_SUPPLEMENTHydrolysed infant formula

Participants in the Hydrolysed infant formula -group received the test formula, casein hydrolysate (Nutramigen™, Mead Johnson Nutritionals), not containing antigenic CM protein, whenever breast milk is not available.

DIETARY_SUPPLEMENTNonhydrolysed infant formula

Participants in the Nonydrolysed infant formula -group received the CM protein containing control formula which has an addition (20 %) of Nutramigen, whenever breast milk is not available.

Sponsors

United States Congress
CollaboratorFED
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
Juvenile Diabetes Research Foundation
CollaboratorOTHER
European Community (EC)
CollaboratorOTHER_GOV
European Foundation for the Study of Diabetes
CollaboratorOTHER
Mead Johnson Nutrition
CollaboratorINDUSTRY
Academy of Finland
CollaboratorOTHER
Diabetes Research Foundation, Finland
CollaboratorOTHER
Dutch Diabetes Research Foundation
CollaboratorOTHER
University of Helsinki
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 7 Days
Healthy volunteers
No

Inclusion criteria

* Biological parent and/or full (not half) sibling of the newborn infant had type 1 diabetes as defined by the World Health Organization * The infant's parent or legal guardians gave signed consent to participate

Exclusion criteria

* An older sibling of the newborn infant had been included in the TRIGR intervention * Multiple gestation * The parents were unwilling or unable to feed the infant cow's milk based products for any reason (e.g., religious, cultural). * The newborn infant had a recognizable severe illness such as those due to chromosomal abnormality, congenital malformation, respiratory failure needing assisted ventilation, enzyme deficiencies, etc. * The gestational age of the newborn infant was less than 35 weeks. * The infant was older than 7 days at randomization. * Inability of the family to take part in the study (e.g. the family has no access to any of the Study Centers, the family has no telephone). * The infant had received any infant formula other than Nutramigen prior to randomization. * No HLA sample drawn before the age of 8 days.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Type 1 Diabetes Mellitus12 and 18 months and annually from 2 years up to 14 yearsNumber of participants with Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age and in the final year of the study.

Secondary

MeasureTime frameDescription
Number of Participants With Diabetes Associated Autoantibodies3, 6, 9, 12, 18 months and annually from 2 years up to 14 yearsDiabetes associated autoantibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12, and 18 months of age, and annually from age 2 to 10-14 years

Countries

Australia, Canada, Czechia, Estonia, Finland, Germany, Hungary, Italy, Luxembourg, Netherlands, Poland, Spain, Sweden, Switzerland, United States

Participant flow

Recruitment details

2002-2007 Recruited through local clinics and obstetrics unit

Participants by arm

ArmCount
Nonhydrolysed Infant Formula
A conventional adapted cow's milk formula supplemented with 20% of the casein hydrolysate.
1,078
Hydrolysed Infant Formula
Hydrolysed Infant Formula missing intact cows milk proteins
1,081
Total2,159

Baseline characteristics

CharacteristicNonhydrolysed Infant FormulaHydrolysed Infant FormulaTotal
Age, Categorical
<=18 years
1078 Participants1081 Participants2159 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous
Age at Last Follow-up
11.96 years11.93 years11.95 years
Age, Continuous
At at randomization
0 years0 years0 years
Ethnicity (NIH/OMB)
Hispanic or Latino
53 Participants53 Participants106 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
987 Participants989 Participants1976 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
38 Participants39 Participants77 Participants
family history of type 1 diabetes
More than one family member with type 1 diabetes
32 Participants45 Participants77 Participants
family history of type 1 diabetes
Only father with type 1 diabetes
367 Participants355 Participants722 Participants
family history of type 1 diabetes
Only mother with type 1 diabetes
522 Participants530 Participants1052 Participants
family history of type 1 diabetes
Only one sibling with type 1 diabetes
157 Participants151 Participants308 Participants
Race (NIH/OMB)
American Indian or Alaska Native
3 Participants3 Participants6 Participants
Race (NIH/OMB)
Asian
10 Participants13 Participants23 Participants
Race (NIH/OMB)
Black or African American
10 Participants16 Participants26 Participants
Race (NIH/OMB)
More than one race
9 Participants6 Participants15 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants9 Participants15 Participants
Race (NIH/OMB)
White
1040 Participants1034 Participants2074 Participants
Region of Enrollment
Australia
51 participants51 participants102 participants
Region of Enrollment
Canada
262 participants265 participants527 participants
Region of Enrollment
Czechia
82 participants82 participants164 participants
Region of Enrollment
Estonia
18 participants17 participants35 participants
Region of Enrollment
Finland
212 participants212 participants424 participants
Region of Enrollment
Germany
57 participants55 participants112 participants
Region of Enrollment
Hungary
12 participants11 participants23 participants
Region of Enrollment
Italy
26 participants28 participants54 participants
Region of Enrollment
Luxembourg
3 participants4 participants7 participants
Region of Enrollment
Netherlands
29 participants24 participants53 participants
Region of Enrollment
Poland
46 participants48 participants94 participants
Region of Enrollment
Spain
31 participants29 participants60 participants
Region of Enrollment
Sweden
47 participants49 participants96 participants
Region of Enrollment
Switzerland
6 participants37 participants43 participants
Region of Enrollment
United States
196 participants199 participants395 participants
Sex: Female, Male
Female
516 Participants505 Participants1021 Participants
Sex: Female, Male
Male
562 Participants576 Participants1138 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
5 / 1,0785 / 1,081
other
Total, other adverse events
1,010 / 1,0781,012 / 1,081
serious
Total, serious adverse events
379 / 1,078377 / 1,081

Outcome results

Primary

Number of Participants With Type 1 Diabetes Mellitus

Number of participants with Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age and in the final year of the study.

Time frame: 12 and 18 months and annually from 2 years up to 14 years

Population: Analysis population consisted of participants with increased genetic risk (defined HLA genotypes) for type 1 diabetes

ArmMeasureValue (NUMBER)
Nonhydrolysed Infant FormulaNumber of Participants With Type 1 Diabetes Mellitus82 participants
Hydrolysed Infant FormulaNumber of Participants With Type 1 Diabetes Mellitus91 participants
Secondary

Number of Participants With Diabetes Associated Autoantibodies

Diabetes associated autoantibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12, and 18 months of age, and annually from age 2 to 10-14 years

Time frame: 3, 6, 9, 12, 18 months and annually from 2 years up to 14 years

Population: Analysis population consisted of participants with increased genetic risk (defined HLA genotypes) for type 1 diabetes

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Nonhydrolysed Infant FormulaNumber of Participants With Diabetes Associated AutoantibodiesIAA+162 Participants
Nonhydrolysed Infant FormulaNumber of Participants With Diabetes Associated AutoantibodiesICA+373 Participants
Nonhydrolysed Infant FormulaNumber of Participants With Diabetes Associated AutoantibodiesGADA+186 Participants
Nonhydrolysed Infant FormulaNumber of Participants With Diabetes Associated AutoantibodiesIA-2A+102 Participants
Hydrolysed Infant FormulaNumber of Participants With Diabetes Associated AutoantibodiesIA-2A+115 Participants
Hydrolysed Infant FormulaNumber of Participants With Diabetes Associated AutoantibodiesGADA+207 Participants
Hydrolysed Infant FormulaNumber of Participants With Diabetes Associated AutoantibodiesICA+394 Participants
Hydrolysed Infant FormulaNumber of Participants With Diabetes Associated AutoantibodiesIAA+183 Participants

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026